Roche ' s Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer

Head-to-head phase III study of Alecensa versus crizotinib in Asian patient population showed a reduction in the risk of disease worsening or death by 78%Alecensa lowered the risk of tumour spread or growth in the brain or central nervous system by 86%Data add to a wealth of evidence, includ (...)
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news